Hepatitis C discussion with Eliav Barr, MD, vice president, infectious disease project and pipeline lead at Merck Research Laboratories in West Point, Pa.
Listen to Eliav Barr, MD, vice president, infectious disease project and pipeline lead at Merck Research Laboratories in West Point, Pa., discuss with Formulary the cost burden of hepatitis C to the healthcare system, what to expect in the hepatitis pipeline in the near future, and the most effective way to manage these drugs on the formulary.
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More